Wade G W & Inc. purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 52,965 shares of the company’s stock, valued at approximately $945,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of TAK. Banque Cantonale Vaudoise purchased a new stake in Takeda Pharmaceutical during the 3rd quarter worth about $36,000. Balentine LLC purchased a new stake in Takeda Pharmaceutical during the 2nd quarter worth about $39,000. Cullen Frost Bankers Inc. increased its holdings in Takeda Pharmaceutical by 647.6% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,213 shares of the company’s stock worth $40,000 after purchasing an additional 1,917 shares during the period. IFP Advisors Inc increased its holdings in Takeda Pharmaceutical by 40.8% during the 3rd quarter. IFP Advisors Inc now owns 2,440 shares of the company’s stock worth $43,000 after purchasing an additional 707 shares during the period. Finally, Moser Wealth Advisors LLC purchased a new stake in Takeda Pharmaceutical during the 3rd quarter worth about $47,000. Institutional investors own 3.54% of the company’s stock.
Separately, Zacks Investment Research downgraded Takeda Pharmaceutical from a “buy” rating to a “sell” rating in a report on Friday, August 7th.
TAK opened at $17.25 on Tuesday. Takeda Pharmaceutical Company Limited has a one year low of $12.43 and a one year high of $20.92. The company has a market cap of $54.38 billion, a P/E ratio of 38.33 and a beta of 0.96. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.84 and a current ratio of 1.22. The business’s 50-day simple moving average is $16.97 and its 200-day simple moving average is $18.00.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines.
Featured Article: What is the definition of market timing?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.